XML 46 R30.htm IDEA: XBRL DOCUMENT
v3.25.1

Note 21 - Demadoctor Divestiture and Discontinued Operations | 12 Months Ended
--- | ---
Dec. 31, 2024
DERMAdoctor [Member] |
Notes to Financial Statements |
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] | NOTE 21. DERMADOCTOR DIVESTITURE AND DISCONTINUED OPERATIONS On March 12, 2024, the Company entered into an agreement to sell 100% of the membership units of DERMAdoctor for a closing purchase price of $1.1 million. The sale of the membership units closed, and the DERMAdoctor Divestiture occurred, on March 25, 2024. In order to close the sale, the Company was required to obtain the consent of the holders of the Secured Convertibles Notes (see Note 13, “Convertible Notes”) issued in May 2023 to (i) amend the Security Agreement, dated April 27, 2023 (the “Security Agreement”) to remove the Membership Units and any assets of DERMAdoctor as collateral for the Company’s obligations pursuant to the Secured Convertible Notes and for DERMAdoctor to be removed as a party to the Security Agreement and (ii) terminate the Subsidiary Guarantee, dated April 27, 2023 (the “Subsidiary Guarantee”), which DERMAdoctor entered into in connection with the issuance of the Secured Convertible Notes. On March 24, 2024, the Company and the secured parties entered into a First Amendment to the Security Agreement, (the “First Amendment and Subsidiary Guarantee Consent”) to effect an amendment to the Security Agreement and a Consent and Release to terminate the Subsidiary Guarantee. To obtain the secured parties’ consent and as consideration for the secured parties taking the necessary actions to execute and deliver the First Amendment and the Subsidiary Guarantee Consent, the Company provided each secured party the option, at the secured party’s election, to receive only upon the closing of the DERMAdoctor Divestiture either: a March 2024 Warrant or the Unsecured Convertible Notes (see Note 13 “Convertible Notes”). The accounting requirements for reporting the DERMAdoctor business as discontinued operations were met during the first quarter of 2024. Accordingly, the consolidated financial statements and notes to the consolidated financial statements reflect the results of the DERMAdoctor business as a discontinued operation for the years presented. In accordance with the provisions of ASC 205-20, Presentation of Financial Statements: Discontinued Operations (“ASC 205-20”) the Company has separately reported the assets and liabilities of the discontinued operations in the consolidated balance sheets. The assets and liabilities have been reflected as discontinued operations in the consolidated balance sheets as of December 31, 2023, and consist of the following (in thousands):
|  | Balance at December 31, 2023 |
ASSETS |  |  |  |
Current assets: |  |  |  |
Cash and cash equivalents |  | $ | 206 |
Accounts receivable, net of allowance for credit losses ($0 at December 31, 2023) |  |  | 79 |
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($363 at December 31, 2023) |  |  | 2,313 |
Prepaid expenses and other current assets |  |  | 132 |
Total current assets, discontinued operations |  |  | 2,730 |
Other assets |  |  | 19 |
Total assets, discontinued operations |  | $ | 2,749 |
LIABILITIES |  |  |  |
Liabilities: |  |  |  |
Current liabilities: |  |  |  |
Accounts payable |  | $ | 224 |
Accrued liabilities |  |  | 347 |
Operating lease liabilities |  |  | 127 |
Total current liabilities, discontinued operations |  |  | 698 |
Total liabilities, discontinued operations |  | $ | 698 |
In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the consolidated statements of operations. The results of DERMAdoctor’s operations for the years ended December 31, 2024 and 2023 have been reflected as discontinued operations in the consolidated statements of operations and consist of the following (in thousands):
|  | For the years ended December 31, |
|  | 2024 |  |  | 2023 |
Sales: |  |  |  |  |  |  |  |
Product revenue, net |  | $ | 717 |  |  | $ | 3,552 |
Total sales, net |  |  | 717 |  |  |  | 3,552 |
Cost of goods sold |  |  | 493 |  |  |  | 2,145 |
Gross profit |  |  | 224 |  |  |  | 1,407 |
Operating expenses |  |  |  |  |  |  |  |
Research and development |  |  | 2 |  |  |  | 34 |
Sales and marketing |  |  | 292 |  |  |  | 1,795 |
General and administrative |  |  | 48 |  |  |  | 883 |
Goodwill, intangible and other asset impairment |  |  | - |  |  |  | 2,593 |
Total operating expenses |  |  | 342 |  |  |  | 5,305 |
Operating loss |  |  | (118 | ) |  |  | (3,898 | )
Other expense, net |  |  | (6 | ) |  |  | (1 | )
Net loss from discontinued operations |  | $ | (124 | ) |  | $ | (3,899 | )
In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the consolidated statements of cash flows. The results of DERMAdoctor for the years ended December 31, 2024 and 2023 have been reflected as discontinued operations in the consolidated statements of cash flows and consist of the following (in thousands):
|  | For the years ended December 31, |
|  | 2024 |  |  | 2023 |
Operating activities: |  |  |  |  |  |  |  |
Net loss from discontinued operations |  | $ | (124 | ) |  | $ | (3,899 | )
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |  |  |  |  |  |
Amortization of intangible assets |  |  | — |  |  |  | 152 |
Impairment of goodwill, intangible and other assets |  |  | — |  |  |  | 2,595 |
Non-cash right-of-use amortization |  |  | — |  |  |  | 112 |
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |
Accounts receivable |  |  | (262 | ) |  |  | 237 |
Inventory |  |  | 183 |  |  |  | 429 |
Prepaid expenses and other current assets |  |  | (4 | ) |  |  | 162 |
Other assets |  |  | 15 |  |  |  | (9 | )
Accounts payable and accrued liabilities |  |  | 63 |  |  |  | (32 | )
Operating lease liabilities |  |  | (31 | ) |  |  | (119 | )
Net cash used in operating activities, discontinued operations |  |  | (160 | ) |  |  | (372 | )
Investing activities: |  |  |  |  |  |  |  |
Cash transferred to New Age Investments, LLC |  |  | (46 | ) |  |  | — |
Purchases of property and equipment |  |  | — |  |  |  | (1 | )
Net cash used in investing activities, discontinued operations |  |  | (46 | ) |  |  | — |
Net decrease in cash and cash equivalents, discontinued operations |  | $ | (206 | ) |  | $ | (373 | )

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-20/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContent + Details
Name: | us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=nby_DermadoctorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |